Cyclosporine Reduction in the Presence of Everolimus: 3-Month Data From a Canadian Pilot Study of Maintenance Cardiac Allograft Recipients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 2, 2008, Pages 197-202

  Ross, Heather ^a   Pflugfelder, Peter ^b   Haddad, Haissam ^c   Cantarovich, Marcelo ^d   White, Michael ^e   Ignaszewski, Andrew ^f   Howlett, Jonathan ^g   Vaillancourt, Marc ^h   Dorent, Richard ⁱ   Burton, Jeffrey R ^j  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MONTREAL HEART INSTITUTE   (Canada)

^f ST PAUL S HOSPITAL   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h Novartis Pharmaceuticals Canada Inc   (Canada)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ADULT; ANGIONEUROTIC EDEMA; ANOREXIA; APHTHOUS STOMATITIS; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EAR INFECTION; EPISTAXIS; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEADACHE; HEART TRANSPLANTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEUKOPENIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; MALAISE; MALE; MICROEMULSION; MOUTH ULCER; MULTICENTER STUDY; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; TONGUE SWELLING; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; CANADA; CONFIDENCE INTERVALS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; RISK ASSESSMENT; SINGLE-BLIND METHOD; SIROLIMUS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 38949126946     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.11.565     Document Type: Article

References (24)

1. Orens J.B., Shearon T.H., Freudenberger R.S., et al. Thoracic organ transplantation in the United States, 1995-2004. Am J Transplant 6 (2006) 1188-1197
2. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 23 suppl (2004) S202-S206
3. Dhaliwal A., and Thohan V. Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation. Curr Atheroscler Rep 8 (2006) 119-130
4. Mehra M.R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6 (2006) 1248-1256
5. Odim J., Wheat J., Laks H., et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 162-166
6. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
7. Bohler T., Waiser J., Budde K., et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 30 (1998) 2195-2197
8. Cao W., Mohacsi P., Shorthouse R., Pratt R., and Morris R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59 (1995) 390-395
9. Schuurman H.-J., Pally C., Weckbecker G., Schuler W., and Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 31 (1999) 1024-1025
10. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
11. Eisen H.J. Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 21 suppl 3 (2006) iii9-iii13
12. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244-252
13. Tomlanovich S.J., and Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2 (2007) 198-199
14. Kuypers D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Safety 28 (2005) 153-181
15. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
16. Lehmkuhl H.B., Mai D., Dandel M., et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 26 (2007) 700-704
17. Rothenburger M., Teerling E., Bruch C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 26 (2007) 250-257
18. Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian consensus conference. J Heart Lung Transplant 24 suppl (2005) S196-S200
19. Nankivell B.J., Gruenewald S.M., Allen R., and Chapman J.R. Predicting glomerular filtration rate after kidney transplantation. Transplantation 59 (1995) 1683-1689
20. Billingham M.E., Cary N.R., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant 9 (1990) 587-593
21. Pascual J. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation 79 suppl (2005) S76-S79
22. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
23. Zuckermann A. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the University of Vienna. J Heart Lung Transplant 24 suppl (2005) S206-S209
24. Schweiger M., Walser A., Prenner G., et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transplant Immunol 16 (2006) 46-51